Larimar Therapeutics Inc
NASDAQ:LRMR
Intrinsic Value
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of LRMR.
Larimar Therapeutics Inc's market capitalization is 407m USD.
LRMR stock price is 6.38 USD.
LRMR.
LRMR. Open DCF Valuation
LRMR. Open Relative Valuation
LRMR has upside potential of 258% compared to the average analyst price target.
Open Wall St Estimates
LRMR has negative Free Cash Flow for the last twelve months.
LRMR has negative Operating Income for the last twelve months.
LRMR has negative Net Income for the last twelve months.
LRMR's ROE (Return on Equity) has significantly increased in the last 3 years from -74% to -38%, and is approaching profitability.
LRMR's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -539% to -590%, and is approaching profitability.
LRMR's ROE (Return on Equity) for the past 12 months is negative and is equal to -38%.
LRMR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -590%.
LRMR has negative three-year average ROE (Return on Equity): -53%. The company is not efficient at transforming stockholders' equity into net income.
LRMR has negative three-year average ROIC (Return on Invested Capital): -548%. The company is not efficient at using invested capital to generate operating income.
LRMR's short-term assets (90m USD) exceed its short-term liabilties (10m USD).
LRMR's long-term assets (96m USD) exceed its long-term liabilties (14m USD).
LRMR's D/E (Debt to Equity) is very low and is equal to 0.
LRMR's Altman Z-Score is very high and is equal to 7.99.
Fundamental Analysis
Larimar Therapeutics Inc
Balance Sheet Decomposition
Larimar Therapeutics Inc
| Current Assets | 90.2m |
| Cash & Short-Term Investments | 86.8m |
| Other Current Assets | 3.4m |
| Non-Current Assets | 5.8m |
| PP&E | 3.8m |
| Other Non-Current Assets | 2m |
| Current Liabilities | 9.5m |
| Accounts Payable | 1.3m |
| Accrued Liabilities | 8.2m |
| Non-Current Liabilities | 4.7m |
| Other Non-Current Liabilities | 4.7m |
Earnings Waterfall
Larimar Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-41.8m
USD
|
|
Operating Income
|
-41.8m
USD
|
|
Other Expenses
|
4.8m
USD
|
|
Net Income
|
-36.9m
USD
|
Free Cash Flow Analysis
Larimar Therapeutics Inc
What is Free Cash Flow?
LRMR Profitability Score
Profitability Due Diligence
Larimar Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Larimar Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
LRMR Solvency Score
Solvency Due Diligence
Larimar Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Larimar Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LRMR Price Targets Summary
Larimar Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
LRMR
is 22.85 USD
with a low forecast of 10.1 USD and a high forecast of 28.35 USD.
Ownership
LRMR Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
LRMR Price
Larimar Therapeutics Inc
| Average Annual Return | -26.14% |
| Standard Deviation of Annual Returns | 61.06% |
| Max Drawdown | -95% |
| Market Capitalization | 407m USD |
| Shares Outstanding | 63 800 000 |
| Percentage of Shares Shorted | 6.96% |
Company Profile
Larimar Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 31 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The firm's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.
You don't have any saved screeners yet
